April 9, 2008

From the News Wire: Tolerx Phase III

WOW lots of news out today! Here another one, one of the JDRF IDDP companies.

Tolerx Advancing Novel Type 1 Diabetes Agent into Phase III Clinical Trial Program Following End of Phase II FDA Meeting

Phase III study will evaluate effects of otelixizumab, an investigational
anti-CD3 monoclonal antibody, on preservation of endogenous insulin secretion

CAMBRIDGE, Mass., April 9, 2008 /PRNewswire/ -- Tolerx, Inc., a
biopharmaceutical company engaged in the discovery and development of novel
therapies for immune-mediated diseases, today announced that it is proceeding
toward the initiation of a Phase III study of otelixizumab in new-onset type 1
diabetes. Tolerx is initiating this pivotal trial after reviewing the
results of the otelixizumab development program with the US Food and Drug
Administration (FDA) at an End of Phase II meeting.